DiaGenic reports AMYtect™ study results
DiaGenic reports final results from an exploratory study that examines the agreement between gene expression in blood and brain amyloid PET imaging. In a patient population of 144 patients, a gene expression biomarker was identified that demonstrated an agreement of 69% with brain amyloid PET imaging.
The primary goal of this exploratory study was to identify a gene expression biomarker which detects whether an individual has normal or elevated levels of amyloid in the brain as determined by brain amyloid PET imaging. The subsequent goal was to develop an IVD multivariate index assay test, AMYtect™. The study included 144 patients from clinical centers coordinated by Lund University in Sweden, of which 118 were diagnosed with suspected mild cognitive impairment and 26 were healthy controls. Blood samples were collected and brain amyloid PET scans using GE Healthcare’s investigational [18F] Flutemetamol tracer were performed for all patients. The results show an agreement of 69% between gene expression in blood and brain amyloid using PET imaging as the reference.
“This study showed a significant correlation between a gene expression biomarker candidate and brain amyloid PET imaging. This is a novel and encouraging result in the quest to identify a blood test to screen for early Alzheimer's patients. However, the correlation reached with the current biomarker panel is not sufficient to warrant clinical development of AMYtect”, said Paul de Potocki, CEO at DiaGenic.
For more information, contact:
Paul de Potocki, CEO at DiaGenic, telephone: +47 2324 8950
About DiaGenic ASA
DiaGenic is an innovative diagnostic company that seeks to create value for patients, partners and investors by developing patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange.